CLN5 and blindness (disorder): However, both moderate- and high-dose ICV delivery of CLN5 gene therapy likely prevented the cortical neurodegenerative-driven blindness seen in untreated CLN5−/− sheep as all treated animals had improved visual function compared with untreated controls, confirming the importance of treating the CNS in combination with the eye to prevent loss of visual function.